E. Alemao

2.0k total citations
118 papers, 1.5k citations indexed

About

E. Alemao is a scholar working on Rheumatology, Surgery and Economics and Econometrics. According to data from OpenAlex, E. Alemao has authored 118 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 55 papers in Rheumatology, 32 papers in Surgery and 29 papers in Economics and Econometrics. Recurrent topics in E. Alemao's work include Rheumatoid Arthritis Research and Therapies (45 papers), Lipoproteins and Cardiovascular Health (27 papers) and Health Systems, Economic Evaluations, Quality of Life (26 papers). E. Alemao is often cited by papers focused on Rheumatoid Arthritis Research and Therapies (45 papers), Lipoproteins and Cardiovascular Health (27 papers) and Health Systems, Economic Evaluations, Quality of Life (26 papers). E. Alemao collaborates with scholars based in United States, Sweden and United Kingdom. E. Alemao's co-authors include Glenn Davies, Donald Yin, J.R. Cook, A. Lawrence Gould, D. Yin, G Nocea, Seán Connolly, Éric Van Ganse, Laurent Laforest and Michael E. Weinblatt and has published in prestigious journals such as SHILAP Revista de lepidopterología, Annals of Internal Medicine and PLoS ONE.

In The Last Decade

E. Alemao

112 papers receiving 1.4k citations

Peers

E. Alemao
Comparison fields: 5 of 100
  • Surgery 517
  • Rheumatology 486
  • Economics and Econometrics 373
  • Endocrinology, Diabetes and Metabolism 338
  • Cardiology and Cardiovascular Medicine 168
Sumesh Kachroo United States
Geert J. M. Boerma Netherlands
Gudrun Nyberg Sweden
Werner Kleophas Germany
Miłosz Jankowski Poland
Lisa Nessel United States
Lucía Cea Soriano Spain
G. Ruf Germany
Rafael Alfonso‐Cristancho United States
Chris Farmer United Kingdom
Sumesh Kachroo United States View profile →
Citations per field, relative to E. Alemao
E. Alemao · 1×
Citations per year, relative to E. Alemao
E. Alemao · 1×

Countries citing papers authored by E. Alemao

Since Specialization
Citations

This map shows the geographic impact of E. Alemao's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by E. Alemao with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites E. Alemao more than expected).

Fields of papers citing papers by E. Alemao

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by E. Alemao. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by E. Alemao. The network helps show where E. Alemao may publish in the future.

Co-authorship network of co-authors of E. Alemao

This figure shows the co-authorship network connecting the top 25 collaborators of E. Alemao. A scholar is included among the top collaborators of E. Alemao based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with E. Alemao. E. Alemao is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
# Title Journal Authors Indexed citations
1 POS0477 RELATIONSHIP BETWEEN SHARED EPITOPE STATUS AND REFRACTORY RHEUMATOID ARTHRITIS Annals of the Rheumatic Diseases Kristin Wipfler, E. Alemao et al. 1
2 Cycling of tumor necrosis factor inhibitors versus switching to different mechanism of action therapy in rheumatoid arthritis patients with inadequate response to tumor necrosis factor inhibitors: a Bayesian network meta-analysis Therapeutic Advances in Musculoskeletal Disease Alberto Migliore, E. Alemao et al. 22
3 PIN33 How Does Mortality Differ In Early Vs. Late Diagnosed Nontuberculous Mycobacterial Lung Disease Among Patients With Chronic Obstructive Pulmonary Disease (COPD) Value in Health Theodore K. Marras, E. Alemao et al. 3
4 Evaluation of the Effect of Diabetes on Rheumatoid Arthritis–related Outcomes in an Electronic Health Record–based Rheumatology Registry The Journal of Rheumatology Huifeng Yun, Fenglong Xie et al. 7
5 Immunosuppression and the risk of readmission and mortality in patients with rheumatoid arthritis undergoing hip fracture, abdominopelvic and cardiac surgery Annals of the Rheumatic Diseases Michael George, Joshua F. Baker et al. 12
6 Trajectories of health-related quality of life among renal transplant patients associated with graft failure and symptom distress: Analysis of the BENEFIT and BENEFIT-EXT trials American Journal of Transplantation Jennifer L. Beaumont, Martin S. Polinsky et al. 15
7 Supplementing Claims Data with Electronic Medical Records to Improve Estimation and Classification of Rheumatoid Arthritis Disease Activity: A Machine Learning Approach ACR Open Rheumatology Candace H. Feldman, Kazuki Yoshida et al. 10
8 Efficacy of Abatacept and Adalimumab in Patients with Early Rheumatoid Arthritis With Multiple Poor Prognostic Factors: Post Hoc Analysis of a Randomized Controlled Clinical Trial (AMPLE) Rheumatology and Therapy Roy Fleischmann, Michael E. Weinblatt et al. 11
9 Do Poor Prognostic Factors in Rheumatoid Arthritis Affect Treatment Choices and Outcomes? Analysis of a US Rheumatoid Arthritis Registry The Journal of Rheumatology E. Alemao, Heather J. Litman et al. 2
10 Conceptual model for the health technology assessment of current and novel interventions in rheumatoid arthritis PLoS ONE E. Alemao, Maiwenn Al et al. 9
11 A window of opportunity for abatacept in RA: is disease duration an independent predictor of low disease activity/remission in clinical practice? Clinical Rheumatology Leslie R. Harrold, Heather J. Litman et al. 13
12 Effect of Anticitrullinated Protein Antibody Status on Response to Abatacept or Antitumor Necrosis Factor-α Therapy in Patients with Rheumatoid Arthritis: A US National Observational Study The Journal of Rheumatology Leslie R. Harrold, Heather J. Litman et al. 39
13 Association of anti-cyclic citrullinated protein antibodies, erosions, and rheumatoid factor with disease activity and work productivity: A patient registry study Seminars in Arthritis and Rheumatism E. Alemao, Zhenchao Guo et al. 16
14 Patient-Reported Outcomes Following 12 Months of Therapy with Abatacept (Plus Methotrexate or as Monotherapy) or Methotrexate and up to 6 Months after Treatment Withdrawal in Patients with Early Rheumatoid Arthritis Data Archiving and Networked Services (DANS) D E Furst, Gerd R Burmester et al. 2
15 Development of a diabetes treatment simulation model: with application to assessing alternative treatment intensification strategies on survival and diabetes‐related complications Diabetes Obesity and Metabolism E. Alemao, D. Yin et al. 28
16 Cost Effectiveness of Adding Ezetimibe to Atorvastatin Therapy in Patients Not at Cholesterol Treatment Goal in Canada PharmacoEconomics Michele Kohli, Cheryl Attard et al. 18
17 Evaluation of Lipid-Lowering Therapy and Cholesterol Goal Attainment in Finland American Journal of Cardiovascular Drugs E. Alemao, Harri Sintonen et al. 15
18 Statins are less effective in common daily practice among patients with hypercholesterolemia: the REALITY-PHARMO study; Current Medical Research and Opinion Wim Goettsch, Donald Yin et al. 27
19 National economic impact of tirofiban for unstable angina and myocardial infarction without ST elevation; example from the United Kingdom International Journal of Cardiology Ameet Bakhai, Marcus Flather et al. 7
20 A meta-analysis of the dose-response relationship of inhaled corticosteroids in adolescents and adults with mild to moderate persistent asthma Clinical Therapeutics Jean Bousquet, Rami Ben‐Joseph et al. 47

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Rankless by CCL
2026